| dbo:abstract | - Ralmitaront (INN, USAN; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing clinical trials for the treatment of acute exacerbation of schizophrenia and schizoaffective disorder. It is a partial agonist of the TAAR1. The medication is being developed by the pharmaceutical company Hoffmann-La Roche. Ralmitaront has completed phase 1 clinical trials. Phase 2 trials are ongoing. (en)
|
| dbo:casNumber | |
| dbo:chEMBL | |
| dbo:fdaUniiCode | |
| dbo:kegg | |
| dbo:pubchem | |
| dbo:thumbnail | |
| dbo:wikiPageID | |
| dbo:wikiPageLength | - 4008 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID | |
| dbo:wikiPageWikiLink | |
| dbp:c | |
| dbp:casNumber | |
| dbp:chembl | |
| dbp:chemspiderid | |
| dbp:h | |
| dbp:iupacName | |
| dbp:kegg | |
| dbp:n | |
| dbp:o | |
| dbp:pubchem | |
| dbp:smiles | |
| dbp:stdinchi | |
| dbp:stdinchikey | - XHHXGKRFUPEPFM-OAHLLOKOSA-N (en)
|
| dbp:synonyms | |
| dbp:unii | |
| dbp:width | |
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment | - Ralmitaront (INN, USAN; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing clinical trials for the treatment of acute exacerbation of schizophrenia and schizoaffective disorder. It is a partial agonist of the TAAR1. The medication is being developed by the pharmaceutical company Hoffmann-La Roche. Ralmitaront has completed phase 1 clinical trials. Phase 2 trials are ongoing. (en)
|
| rdfs:label | |
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| isdbo:wikiPageWikiLink of | |
| isfoaf:primaryTopic of | |
